Mission Statement

The Digital Community serves as the most robust resource for clinical data, case examples, and program development for Protected PCI and hemodynamic support for the treatment of Cardiogenic Shock for interventional cardiologists and the broader cardiology community.

  • ABOUT THIS SITE
  • ABOUT IMPELLA
  • EDITORIAL BOARD
 Welcome to the Protected PCI community, the largest source of education and reference materials on pVADs and the Impella® platform.  Here physicians and health care professionals can learn and share knowledge about the latest advances in The Science of Heart Muscle Recovery; the treatment of high risk patients with protected PCI, and Cardiogenic Shock Therapy. The community is brought to you by ABIOMED, Inc. — a leading provider of breakthrough heart support technologies.

ABIOMED created this community to keep you informed of the latest developments in interventional cardiology, and to create a place where innovators in the field can discuss its latest developments.  Use it to keep up with news and information about the latest breakthroughs in cardiac research, relevant journal articles, guidelines, and educational opportunities.  As this community grows, it will become the online meeting place for some of the most innovative and authoritative voices in our field.

Please subscribe now to join our community and stay informed whenever new content is published.

To learn more about the Impella platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit www.protectedpci.com/hcp/information/isi and www.cardiogenicshock.com.

  • Provides direct left ventricular unloading by pulling blood from the left ventricle and expelling it into the aorta, increasing total cardiac output/arterial pressure and reducing myocardial oxygen consumption
  • Provides forward blood flow of up to 2.5 L/min
  • 9F catheter providing 12F axial flow
  • The Impella 2.5 is a temporary (< 6 hours) ventricular support device indicated for use during high risk percutaneous coronary interventions (PCI) performed in elective or urgent, hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction, when a heart team, including a cardiac surgeon, has determined high risk PCI is the appropriate therapeutic option
  • Use of the Impella 2.5 in these patients may prevent hemodynamic instability which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri- and post-procedural adverse events
  • Warnings and Contraindications

The Impella 2.5 is contraindicated for use with patients experiencing any of the following conditions: (1) mural thrombus in the left ventricle; (2) Mechanical aortic valve or heart constrictive device; (3) Aortic valve stenosis/calcification (equivalent to an orifice of 0.6 cm2 or less); (4) Moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ? +2); and (5) Severe peripheral arterial disease that precludes the placement of the Impella® 2.5

Additionally, potential for the following risks has been found to exist with use of the Impella 2.5: Acute renal dysfunction; Aortic insufficiency; Aortic valve injury; Atrial fibrillation; Bleeding; Cardiogenic shock; Cardiac tamponade; Cardiopulmonary resuscitation; Cerebral vascular accident/Stroke; Death; Device malfunction; Failure to achieve angiographic success; Hemolysis; Hepatic failure; Insertion site infection; Limb ischemia; Myocardial infarction; Need for cardiac, thoracic or abdominal operation; Perforation; Renal failure; Repeat revascularization; Respiratory dysfunction; Sepsis; Severe hypotension; Thrombocytopenia; Thrombotic vascular (non-CNS) complication; Transient ischemic attack; Vascular injury; Ventricular arrhythmia, fibrillation or tachycardia

Editorial Board Members

drbilloneillWilliam (Bill) O’Neill, M.D., FACC, FSCAI Medical Director of the Center for Structural Heart Disease and Henry Ford Hospital (Detroit, Mich.)

drjeffreymosesJeffrey W. Moses, M.D., FSCAI

Professor of Medicine at Colombia University College of Physicians and Surgeons; Director for Interventional Vascular Therapy at New York Presbyterian Hospital/Colombia University Medical Center (New York, N.Y.)

drjeffreypopma

Dr. Jeffrey Popma, M.D. FACC, FSCAI

Director of CVI’s Interventional Clinical Cardiology and BIDMC Angiographic Core Laboratory, Beth Israel Deaconess Medical Center; Professor of Medicine, Harvard Medical School (Boston, Mass.)

drpeterduffyPeter Duffy, M.D., MMM, FACC, FSCAI

Director of Quality for the Cardiovascular Service Line at FirstHealth of the Carolinas Reid Heart Institute/Moore Regional Hospital (Pinehurst, N.C.)

drgeorgevetrovecGeorge Vetrovec, M.D., MACC, MSCAI

Martha and Harold Kimmerling Eminent Professor of Medicine at Virginia Commonwealth University (Richmond, Va.)

drjohnlasalaJohn Lasala, M.D., Ph.D., FACC, FSCAI

Professor of Medicine at Washington University School of Medicine; Director of the Structural Heart Disease program at Washington University/Barnes-Jewish Hospital (St. Louis, Mo.)

drdanburkhoffDan Burkhoff, M.D., Ph.D.

Director of Heart Failure, Hemodynamics and Circulatory Support in the CRF Clinical Trials Center (CTC) at the Cardiovascular Research Foundation; Adjunct Associate Professor of Medicine at Columbia University Medical School (New York, N.Y.)